Nonalcoholic Steatohepatitis (NASH) Market is Expected to Grow at a Healthy Growth Rate by 2032, States DelveInsight | Key Companies - Akero Therapeutics (efruxifermin (EFX)), Madrigal Pharmaceuticals (Resmetirom), Genfit, Allergan, Gilead, Galmed, Immuro

DelveInsight's "Nonalcoholic Steatohepatitis (NASH) Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Nonalcoholic Steatohepatitis Market Size and Share in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Nonalcoholic Steatohepatitis market report covers emerging drugs, treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Nonalcoholic Steatohepatitis (NASH): An Overview
Nonalcoholic Steatohepatitis (NASH) is the progressive form of liver injury that carries a risk of progressive fibrosis, cirrhosis, and end-stage liver disease. It is an advanced form of nonalcoholic fatty liver disease (NAFLD) caused by the buildup of fat in the liver. When this buildup causes inflammation and damage, it is known as NASH, leading to liver scarring. Scarring of the liver is a potentially life-threatening condition called cirrhosis.

Nonalcoholic Steatohepatitis (NASH) Market Key Facts
• Of all the prevalent cases of NAFLD in the 7MM, approximately 19% of the population fulfilled the criteria for NASH. These cases are expected to increase by 2032.
• As per DelveInsight, the highest prevalence of NASH in the United States accounts for nearly 50% of the total prevalent cases, followed by Japan.
• It is observed that among the European countries, Germany accounted for the highest prevalent population, followed by Italy. Among all the 7MM countries, Spain had the lowest prevalent population.

Request for Sample PDF:
https://www.delveinsight.com/report-store/nonalcoholic-steatohepatitis-nash-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Nonalcoholic Steatohepatitis (NASH) Market
As per DelveInsight, the Nonalcoholic Steatohepatitis Market size is expected to increase in the coming years, owing to the launch of upcoming therapies. The expected launch of emerging therapies will fill the void in treatment areas shortly. The targeted therapies will have stronger penetration than the off-label therapies. The advancement in diagnostic technologies for NASH will also significantly influence the market size.

The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Nonalcoholic Steatohepatitis market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the Nonalcoholic Steatohepatitis market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Download the Sample Pages to Discover More About the Report Offerings:
https://www.delveinsight.com/report-store/nonalcoholic-steatohepatitis-nash-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Nonalcoholic Steatohepatitis (NASH) Epidemiology
The epidemiology section covers detailed insights into the historical and current Nonalcoholic Steatohepatitis patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032.

Nonalcoholic Steatohepatitis (NASH) Epidemiology Segmentation -
• Total Prevalent Cases of Non-Alcoholic Fatty Liver Disease
• Total Prevalent cases of Nonalcoholic Steatohepatitis
• Nonalcoholic Steatohepatitis Segmentation by Fibrosis Stage

Nonalcoholic Steatohepatitis (NASH) Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Nonalcoholic Steatohepatitis market or expected to get launched in the market during the study period. The analysis covers Nonalcoholic Steatohepatitis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Report's Drugs Uptake section helps in understanding the drugs with the most rapid uptake and reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Nonalcoholic Steatohepatitis Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Recent Developments in the Nonalcoholic Steatohepatitis (NASH) Market
• On September 14, 2022, Akero Therapeutics announced positive top-line data from its phase IIB HARMONY study. The study evaluated the safety and efficacy of efruxifermin (EFX) in patients with pre-cirrhotic non-alcoholic steatohepatitis (NASH), fibrosis stage 2 or 3 (F2-F3).

• On August 31, 2022, Madrigal Pharmaceuticals announced the initiation of the "MAESTRO-NASH Outcomes" study of resmetirom (recruiting the first patient screened). "MAESTRO-NASH Outcomes" is a Phase 3, double-blind, randomized, placebo-controlled study that will noninvasively measure progression to liver decompensation events in approximately 700 patients with compensated NASH cirrhosis.

Explore More About Clinical and Commercial Development Activities:
https://www.delveinsight.com/sample-request/nonalcoholic-steatohepatitis-nash-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Some of the key companies in the Nonalcoholic Steatohepatitis (NASH) Market include
Genfit, Intercept Pharmaceuticals, Allergan (Tobira Therapeutics), Gilead Sciences, Galmed Pharmaceuticals Ltd., Bristol-Myers Squibb (BMS), Immuron, Galectin Therapeutics, Cirius Therapeutics, NGM Biopharmaceuticals, TaiwanJ Pharmaceuticals, Novo Nordisk, Mitsubishi Tanabe Pharma, Novartis Pharmaceuticals, MediciNova, Madrigal Pharmaceuticals, Can-Fite BioPharma, Oramed Pharmaceuticals, Ascletis Pharma, Terns Pharmaceuticals, Enyo Pharma, and many others.

Nonalcoholic Steatohepatitis (NASH) Therapies covered in the report include:
Elafibranor (GFT505), Obeticholic Acid (OCA, Ocaliva), Selonsertib (SEL, Formerly GS-4997), Cenicriviroc (CVC), Cilofexor (GS-9674), Firsocostat (GS-0976), Aramchol, Pegbelfermin (BMS-986036), IMM-124E, Belapectin (GR-MD-02), MSDC-0602K, NGM282 (aldafermin), JKB-122, Semaglutide, MT-3995 (Apararenone), LJC242, LJN452 (Tropifexor), MN-001 (Tipelukast), Resmetirom (MGL-3196), Namodenoson (CF102), ORMD-0801, ASC40, TERN-101, EYP001, and many more

Learn More About the Emerging Therapies & Key Companies in the Nonalcoholic Steatohepatitis Therapeutics Market:
https://www.delveinsight.com/sample-request/nonalcoholic-steatohepatitis-nash-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Nonalcoholic Steatohepatitis Competitive Intelligence Analysis
4. Nonalcoholic Steatohepatitis Market Overview at a Glance
5. Nonalcoholic Steatohepatitis Disease Background and Overview
6. Nonalcoholic Steatohepatitis Patient Journey
7. Nonalcoholic Steatohepatitis Epidemiology and Patient Population
8. Nonalcoholic Steatohepatitis Treatment Algorithm, Current Treatment, and Medical Practices
9. Nonalcoholic Steatohepatitis Unmet Needs
10. Key Endpoints of Nonalcoholic Steatohepatitis Treatment
11. Nonalcoholic Steatohepatitis Marketed Products
12. Nonalcoholic Steatohepatitis Emerging Therapies
13. Nonalcoholic Steatohepatitis Seven Major Market Analysis
14. Attribute Analysis
15. Nonalcoholic Steatohepatitis Market Outlook (7 major markets)
16. Nonalcoholic Steatohepatitis Access and Reimbursement Overview
17. KOL Views on the Nonalcoholic Steatohepatitis Market.
18. Nonalcoholic Steatohepatitis Market Drivers
19. Nonalcoholic Steatohepatitis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

Get the Detailed TOC of the Nonalcoholic Steatohepatitis Market report here:
https://www.delveinsight.com/sample-request/nonalcoholic-steatohepatitis-nash-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Anuj Rawat
Email: info@delveinsight.com
https://www.delveinsight.com/

428, D21 Corporate Park,
Sector-21, Dwarka,
New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.